Sera Prognostics(US:SERA)2025-11-13 21:09Financial Performance - Third quarter 2025 revenue was $16,000, a decrease from $29,000 in the same quarter of 2024[6] - Total operating expenses for Q3 2025 were $9.0 million, slightly up from $8.9 million in Q3 2024[6] - The net loss for Q3 2025 was $7.8 million, a slight improvement from a net loss of $7.9 million in Q3 2024[9] Expenses Breakdown - Research and development expenses decreased to $3.3 million in Q3 2025 from $3.5 million in Q3 2024, reflecting lower clinical study costs[7] - Selling, general and administrative expenses rose to $5.7 million in Q3 2025, compared to $5.4 million in the prior-year period[8] Cash Position - As of September 30, 2025, the company had cash, cash equivalents, and available-for-sale securities totaling approximately $102.4 million[9] Market Opportunities - The company is advancing discussions with managed Medicaid plans covering 33% of U.S. births and 35% of Medicaid births annually, indicating a significant commercial opportunity[3] Product Impact - The PreTRM Test is associated with a 20% reduction in NICU admissions, highlighting its potential impact on maternal and neonatal outcomes[5] - The company is on track to publish full results of the PRIME study this year, which will include health economic benefits and expected cost-saving benefits of the PreTRM Test[4] Leadership Changes - Sera Prognostics has strengthened its leadership team with the appointment of Dr. Tiffany Inglis as Chief Medical Officer and Marisol Urbano as Head of Commercial Operations[4]